CO4480036A1 - Proteinas anti-obesidad - Google Patents

Proteinas anti-obesidad

Info

Publication number
CO4480036A1
CO4480036A1 CO96003535A CO96003535A CO4480036A1 CO 4480036 A1 CO4480036 A1 CO 4480036A1 CO 96003535 A CO96003535 A CO 96003535A CO 96003535 A CO96003535 A CO 96003535A CO 4480036 A1 CO4480036 A1 CO 4480036A1
Authority
CO
Colombia
Prior art keywords
xaa
gln
glu
asp
asn
Prior art date
Application number
CO96003535A
Other languages
English (en)
Inventor
Richard D Dimarchi
Jr William F Heath
Barbara Basinski Margret
Brigitte Elisabeth Schoner
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO4480036A1 publication Critical patent/CO4480036A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

UNA PROTEINA DE FORMULA (I): FIGURA 1 EN DONDE: Xaa EN LA POSICION 4 ES Gln o Glu; Xaa EN LA POSICION 7 ES Gln o Glu; Xaa EN LA POSICION 22 ES Gln, Asn o Asp; Xaa EN LA POSICION 27 ES Thr o Ala; Xaa EN LA POSICION 28 ES Gln, Glu, o AUSENTE; Xaa EN LA POSICION 34 ES Gln o Glu; Xaa EN LA POSICION 54 ES Met, metionina sulfoxido, Leu, Ile, Val, Ala o Gly; Xaa EN LA POSICION 56 ES Gln o Glu; Xaa EN LA POSICION 62 ES Gln o Glu; Xaa EN LA POSICION 63 ES Gln o Glu; Xaa EN LA POSICION 68 ES Met, metionina sulfoxido, Leu, Ile, Val, Ala o Gly; Xaa EN LA POSICION 72 ES Gln, Asn, o Asp; Xaa EN LA POSICION 75 ES Gln o Glu; Xaa EN LA POSICION 78 ES Gln, Asn o Asp; Xaa EN LA POSICION 82 ES Gln, Asn o Asp; Xaa EN LA POSICION 100 ES Glu, Trp, Phe, Ile, Val o Leu; Xaa EN LA POSICION 108 ES Asp o Glu....
CO96003535A 1995-01-31 1996-01-29 Proteinas anti-obesidad CO4480036A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38104895A 1995-01-31 1995-01-31
US38363895A 1995-02-06 1995-02-06

Publications (1)

Publication Number Publication Date
CO4480036A1 true CO4480036A1 (es) 1997-07-09

Family

ID=27009220

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96003535A CO4480036A1 (es) 1995-01-31 1996-01-29 Proteinas anti-obesidad

Country Status (10)

Country Link
EP (2) EP0725078A1 (es)
JP (1) JPH10513450A (es)
AR (1) AR002024A1 (es)
AU (1) AU4766196A (es)
CA (1) CA2211664A1 (es)
CO (1) CO4480036A1 (es)
PE (1) PE15297A1 (es)
TR (1) TR199600084A2 (es)
WO (2) WO1996023517A1 (es)
YU (1) YU5396A (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6357096A (ja) * 1986-08-29 1988-03-11 工業技術院長 紐体切断装置
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
EP0736599A3 (en) * 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd The rat obesity gene, its gene product and its production
US5614379A (en) * 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
US5840517A (en) * 1995-04-26 1998-11-24 Eli Lilly And Company Process for preparing obesity protein analogs
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
ZA963530B (en) * 1995-05-05 1996-11-05 Hoffmann La Roche Recombinant obese (ob) proteins
PE50997A1 (es) * 1995-05-19 1997-12-18 Lilly Co Eli Producto del gen de la obesidad
AU5800696A (en) * 1995-05-26 1996-12-11 Eli Lilly And Company Rhesus ob protein and dna
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
JPH11512296A (ja) * 1995-09-19 1999-10-26 イーライ・リリー・アンド・カンパニー 医療用タンパク質をコードしているｄｎａ
AU1406497A (en) * 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
US6225446B1 (en) 1995-12-06 2001-05-01 Schering Corporation Mutational variants of mammalian proteins
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
WO1997026011A1 (en) * 1996-01-19 1997-07-24 Eli Lilly And Company Obesity protein formulations
AU1705197A (en) * 1996-01-19 1997-08-11 Eli Lilly And Company Obesity protein formulations
AU2243997A (en) * 1996-01-19 1997-08-11 Eli Lilly And Company Obesity protein formulations
JP2000505791A (ja) * 1996-01-25 2000-05-16 イーライ・リリー・アンド・カンパニー 肥満症タンパク質類似体化合物およびその製剤
EP0889737A1 (en) * 1996-02-06 1999-01-13 Eli Lilly And Company Obesity protein compounds and formulations thereof
HUP0000280A3 (en) * 1996-03-01 2002-09-30 Amgen Inc Thousand Oaks Canine ob protein compositions and methods
WO1997035620A1 (en) * 1996-03-26 1997-10-02 Eli Lilly And Company Formulations of ob protein
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
AU4160597A (en) * 1996-08-23 1998-03-06 Eli Lilly And Company Protein formulations
WO1998016545A1 (en) * 1996-10-11 1998-04-23 Eli Lilly And Company Therapeutic proteins
AU5654998A (en) * 1996-12-06 1998-06-29 F. Hoffmann-La Roche Ag Muteins of obese protein
CA2275446A1 (en) * 1996-12-20 1998-07-02 Eli Lilly And Company Protein crystals, their preparation and use
CA2217698A1 (en) * 1996-12-20 1998-06-20 Eli Lilly And Company Anti-obesity proteins
AU5802898A (en) * 1996-12-20 1998-07-17 Eli Lilly And Company Anti-obesity proteins
AU5919998A (en) * 1997-01-17 1998-08-07 Eli Lilly And Company Obesity protein formulations
US5965521A (en) * 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
AU6655898A (en) * 1997-02-25 1998-09-09 Eli Lilly And Company Modulation of the hypothalamic-pituitary-adrenal-adipose axis with leptin receptor ligands
AU1208599A (en) * 1997-10-31 1999-05-24 Eli Lilly And Company Glycosylated obesity protein analogs
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
EP1128840A1 (en) * 1998-10-27 2001-09-05 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
DE60237100D1 (de) 2001-10-22 2010-09-02 Amgen Inc Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
EP1916239A4 (en) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd PYRIDONE COMPOUND
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
BRPI0618354B8 (pt) 2005-11-10 2021-05-25 Banyu Pharma Co Ltd composto e seu uso, composição farmacêutica, preventivo ou remédio
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
EP2272841A1 (en) 2008-03-28 2011-01-12 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
CA2725143A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009277736A1 (en) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
EP2352510A4 (en) 2008-11-04 2012-08-29 Neurotez Inc LEPTIN COMPOSITIONS AND METHODS OF TREATING PROGRESSIVE COGNITIVE DISORDERS DUE TO THE ASSEMBLY OF NEUROFIBRILLARY BUNNELS AND AMYLOID BETA
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2416797A4 (en) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA3138758A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Highly soluble leptins
MA34916B1 (fr) 2011-02-25 2014-02-01 Merck Sharp & Dohme Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
JP6040464B2 (ja) 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
DE102012106607B4 (de) 2012-07-20 2024-04-04 Heliatek Gmbh Verfahren zur Versiegelung von Modulen mit optoelektronischen Bauelementen
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2017002610A (es) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
EA201990720A1 (ru) 2016-09-12 2019-08-30 Эгерион Фармасьютикалс, Инк. Способы детекции нейтрализующих антител к лептину
CA3038185A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
MX2021005904A (es) 2018-11-20 2021-09-08 Tes Pharma S R L Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.
AU2021233745A1 (en) * 2020-03-11 2022-11-03 Anygen Co., Ltd. Composition for anti-diabetes and anti-obesity comprising novel compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
IL105406A (en) * 1992-04-17 2000-01-31 Sankyo Co Derivatives of adipogenesis inhibitory factor processes for the preparation thereof and pharmaceutical compositions containing the same
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Also Published As

Publication number Publication date
TR199600084A2 (tr) 1996-08-21
CA2211664A1 (en) 1996-08-08
EP0725079A1 (en) 1996-08-07
JPH10513450A (ja) 1998-12-22
PE15297A1 (es) 1997-05-22
EP0725078A1 (en) 1996-08-07
WO1996023517A1 (en) 1996-08-08
WO1996023515A1 (en) 1996-08-08
YU5396A (sh) 1998-08-14
AU4766196A (en) 1996-08-21
AR002024A1 (es) 1998-01-07

Similar Documents

Publication Publication Date Title
CO4480036A1 (es) Proteinas anti-obesidad
AU4188789A (en) Urethane-protected amino acid-n-carboxyanhydrides
TR199802534T2 (xx) Leptin (OB Protein) fragmanlar�
DE69328489D1 (de) Stress-proteine epitopen
MX9301655A (es) Purificacion de proteina.
BR9006934A (pt) Formulacoes aquosas estabilizadas de pequenos peptidios
ATE162201T1 (de) Cnp-gen und vorläuferprotein aus schwein
MD1652G2 (ro) Proteină cu activitate de tip citochină, ADN recombinant, codificator pentru această proteină, celule şi microorganisme transformate, vector de expresie, procedeu de obţinere a proteinei şi remediu care conţine această proteină
ES2060764T3 (es) Composicion cosmetica.
NO942553L (no) Ny humanproteaseinhibitor av Kunitz-type og varianter derav
YU29596A (sh) Genski proizvodi koji regulišu gojaznost
DE122007000030I1 (de) Für menschliches Papillomavirus stamm 18 kodierende DNS
CA2002924A1 (en) Anti-Thrombins
CO4700343A1 (es) Proteinas antiobesidad
CO4480035A1 (es) Proteinas anti-obesidad
NO975565L (no) Benstimulerende faktor
ATE309359T1 (de) Epil/plazentin
ES2097368T3 (es) Nuevas proteinas inhibidoras de trombina a partir de sanguijuelas terrestres.
ECSP972344A (es) Proteinas antiobesidad
ES2171157T3 (es) Gen recombinante codificante para una proteina con actividad endoquitinasa.
PT789761E (pt) Scf humano, uma respectiva variante de processamento, sua utilizacao farmaceutica
DE3883199D1 (de) Fc-bindendes protein und stamm zu dessen herstellung.
ES2191785T3 (es) Proteina de accion antitumoral.
RU97114945A (ru) Белки против ожирения
KR970022737U (ko) 와이퍼 링케이지 피봇의 차체 결합구조